![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pooled Resistance Analyses of Darunavir (DRV) Once-daily (QD) Regimens and Formulations Across 10 Clinical Studies of
Treatment-naïve (TN) and Treatment-experienced (TE) Patients With Human Immunodeficiency Virus (HIV)-1 Infection
|
|
|
IDWeek, October 2-6, 2019, Washington, DC
Reported by Jules Levin
Erkki Lathouwers,1 Sareh Seyedkazemi,2 Donghan Luo,3 Kimberley Brown,3 Sandra De Meyer,1 Eric Y. Wong2
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Janssen Research & Development, LLC, Titusville, NJ, USA.
![1021191](../images/102119/102119-4/1021191.gif)
![1021192](../images/102119/102119-4/1021192.gif)
![1021193](../images/102119/102119-4/1021193.gif)
![1021194](../images/102119/102119-4/1021194.gif)
![1021195](../images/102119/102119-4/1021195.gif)
![1021196](../images/102119/102119-4/1021196.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|